NASDAQ: VTRS

Viatris (VTRS) Stock Analysis & Forecast

Nov 13 close

$20.82+0.15 (+0.7%)

Gekko Brief

AI summaryNov 9 close

Viatris moved on third-quarter results and guidance this week. The company reported nearly flat third-quarter revenue of $3.7495 billion, with adjusted EPS up 6%, while the U.S. GAAP net loss widened due to a higher income tax provision. Despite the revenue miss, Viatris beat EBITDA forecasts on lower operating expenses and raised its 2026 guidance midpoints across key financial metrics. Analyst reaction followed, with Jefferies raising its price target to $22 from $20 while maintaining a Buy rating, and JP Morgan lifting its target to $21 from $20 while keeping a Neutral rating. Commentary also pointed to Viatris's strategic shift toward complex generics, new launches, pipeline progression and cost savings for long-term growth.

Viatris shares closed at $20.49, up 2.9%, sitting above both the 50-day average of $17.78 and the 200-day average of $16.09, within the 52-week range topped by $20.53. The stock has returned 16.2% over one month and 102.7% over one year. The GekkoIndex reads 43.2, placing the stock in the Distribution zone, down 8.1 over five days. Price sits 4.7% above Gekko Fair Value of $19.57.

The next earnings date is 25 February 2027, 102 days away, outside a typical 20-trading-day hold. No insider, Congress, or unusual options activity (30-day window) appears in the current period, though four billionaire holders are noted. Seasonality from this calendar point has averaged +2.2% over the next 20 trading days across 5 years, rising in 3 of them. Analyst consensus across 9 firms shows 5 buy, 3 hold, 1 sell, with a consensus target of $20.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Viatris price vs fair value

$20.82$19.31Nov ’25May ’26Nov ’26
Close $20.82200-day averageGekko Fair Value $19.31

Viatris quick facts

Market cap
$23.87B
P/E ratio
—
Forward P/E
7.7
EPS, TTM
−$0.53
Revenue, TTM
$14.73B
Profit margin
-4.1%
Dividend yield
2.28%
Beta
0.87
Volume
6.51M avg 9.55M
1-year return
+89.1%
Typical daily move
±2.9%
Typical 20-day move
±6.7%
50-day average
$18.11
200-day average
$16.24
Next earnings
Feb 25 before open
Shares outstanding
1.15B
52-week range
$10.15$21.20

Viatris swing-trade checklist

Viatris scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $20.82 is above the 50-day ($18.11) and 200-day ($16.24) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    46.3, Neutral

    Reading 46.3 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    7.8% above

    Price is 7.8% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +1.5% on average

    From this point in the calendar, the next 20 trading days averaged +1.5% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Viatris stock chart and price history

Viatris closed at $20.82 on Nov 13, 2026, +89.1% over the past year, inside a 52-week range of $10.15 to $21.20.

Close50-day average200-day averageVolume
Viatris share price, past year, with 50-day and 200-day moving averages and volume$10$15$20DecJan 2026FebMarAprMayJunJulAugSepOctNov20.82

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+14.3%
3 months
+28.3%
6 months
+26.3%
1 year
+89.1%
The full VTRS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VTRS in Gekko

Follow Viatris through every session

Put VTRS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track VTRS in GekkoFree for 7 days. No credit card required.

About Viatris

Viatris makes and supplies medicines and related health products worldwide, spanning branded drugs, generic and complex generic versions, biosimilars, and active pharmaceutical ingredients. Its medicines cover a wide span of conditions, from long-term illnesses to infectious disease, with biosimilar treatments aimed at areas such as cancer care, immune disorders, hormone conditions, eye disease, and skin conditions. Familiar names in its lineup include Lyrica, Lipitor, EpiPen, Viagra, and Celebrex, alongside biosimilar products like Fulphila, Ogivri, Hulio, and SEMGLEE.

The company is organized into four regional segments covering developed markets, Greater China, Japan/Australia/New Zealand, and emerging markets. It sells medicines in forms ranging from pills and injectables to raw ingredients, reaching pharmacies, wholesalers, hospitals, governments, and insurers through channels that include mail-order and specialty pharmacy networks. Beyond selling drugs, it offers services such as diagnostic clinics, health education, and digital tools, and it works with partners including Biocon, Theravance Biopharma, and Fujifilm Kyowa Kirin Biologics on development and licensing.

Viatris was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Its shares are listed on the NASDAQ under the ticker VTRS.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
viatris.com

Viatris GekkoIndex: the smart money zone

Viatris’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.3, in the Neutral zone, down 0.9 points over five sessions.

010046.3Neutral

Down 0.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying32+1.0%+0.7%−0.2%−4.1%
Accumulation205+0.1%+0.1%+0.4%+1.3%
Neutral (current zone)402+0.6%+1.6%+3.3%+6.6%
Distribution55+0.7%+0.2%−0.7%+3.1%
Selling8Too few readings yet

Average VTRS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the VTRS price, zone by zone.Track VTRS in Gekko

Is Viatris stock overvalued? Gekko Fair Value

Viatris trades 7.8% above Gekko Fair Value of $19.31, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Viatris shares are worth, recalculated every trading day.

$19.31

Gekko Fair Value, Nov 14, 2026

7.8% Overvalued

At the end of Aug 2026 the price was 15.4% below the estimate.

Gekko Fair ValueShare price, month end
$19$21Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open VTRS in Gekko

Viatris insider and Congress trading

No open-market insider purchases were filed for Viatris, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for VTRS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every VTRS insider filing, plotted on the chart in Gekko.Open VTRS in Gekko

Congress trades last 90 days

No trades in VTRS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for VTRS, plotted on the chart in Gekko.Open VTRS in Gekko

Buybacks

Viatris has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$150.0M
As a share of market cap
0.63%

From company filings.

Hedge funds and billionaires quarter ended Sep 30

1of the funds Gekko tracks holds VTRS.

0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Viatris earnings: next date and track record

Viatris reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±8.8%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+11.6%Nov ’24−17.9%Feb ’25+2.0%May ’25+10.9%Aug ’25−5.9%Nov ’25−7.2%Feb ’26+7.6%May ’26−6.9%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
Viatris reported a strong Q2 2026 with $3.8 billion in revenue (≈3.5% operational growth), adjusted EBITDA of $1.2 billion and adjusted EPS of $0.69, results management said exceeded expectations and allowed them to raise 2026 guidance. Commercial execution was highlighted across regions, led by Greater China, with strength in complex generics and transdermal products in North America and growth in developed market generics. Key pipeline and regulatory milestones include FDA approval of Gwyn Lo (once-weekly transdermal contraceptive) with launch planned later in 2026, ongoing NDA review for fast-acting meloxicam with an expected PDUFA year-end, positive Phase III results for Nefecon in Japan, and Phase III programs for selatogrel and cenerimod on track with readouts expected in 2027. Management emphasized execution on an enterprise-wide strategic review delivering operating leverage and cost containment, ongoing remediation at the Nashik manufacturing site after fire and inspection observations, and active M&A and capital allocation including potential buybacks/dividends. Confidence about China as a durable growth engine was tempered by potential provincial-level policy changes that could mute hospital-channel growth in H2. Overall tone was constructive and confident about the strategy and near-term catalysts, while acknowledging discrete operational and policy risks.
Guidance
Management said it has raised its 2026 outlook across key financial metrics (revenue and adjusted EBITDA) based on H1 strength; at the midpoint management indicated revenue was raised by about $50 million and adjusted EBITDA by about $100 million relative to prior guidance. Management expects multiple regulatory milestones and launches in the coming quarters (Gwyn Lo launch later in 2026; PDUFA for fast-acting meloxicam toward year-end). Selatogrel and cenerimod Phase III readouts are expected in 2027. No detailed numeric full-year guidance ranges were provided on the call beyond the statements above.
Risks flagged
Nashik manufacturing fire and FDA inspection observations requiring remediation (supply impacts in H2 2026); potential Chinese provincial-level policy changes affecting hospital procurement channels (could mute China growth); heightened competition in certain North America products and established brands; possible U.S. generic tariffs (policy details unclear); clinical and regulatory risk for pipeline programs (selatogrel, cenerimod, meloxicam); supply constraints for high-demand products (e.g., estradiol patches).
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026$0.69
est $0.62
+11.3%$3.76B
est $3.68B
+2.2%−6.9%
May 7, 2026$0.59
est $0.50
+18.0%$3.52B
est $3.36B
+4.8%+7.6%
Feb 26, 2026$0.57
est $0.52
+9.6%$3.70B
est $3.53B
+4.8%−7.2%
Nov 6, 2025$0.67
est $0.62
+7.9%$3.76B
est $3.62B
+3.8%−5.9%
Aug 7, 2025$0.62
est $0.56
+11.5%$3.58B
est $3.47B
+3.3%+10.9%
May 8, 2025$0.50
est $0.49
+2.0%$3.25B
est $3.24B
+0.6%+2.0%
Feb 27, 2025$0.54
est $0.57
−5.6%$3.53B
est $3.60B
−2.0%−17.9%
Nov 7, 2024$0.75
est $0.68
+10.3%$3.74B
est $3.72B
+0.6%+11.6%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Viatris stock forecast and analyst price targets

Analysts’ average 12-month price target for Viatris is $21.00, +0.9% from the last close, from 9 firms rating the stock in the last 90 days.

$21.00consensus 12-month target, +0.9% from the last close
Low $14High $28
Buy5
Hold3
Sell1

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13BarclaysBuy, maintained$25+20.1%
Nov 9UBSBuy, reiterated$28+34.5%
Nov 6J.P. MorganHold, maintained$21+0.9%
Nov 6UBSBuy, reiterated$28+34.5%
Oct 26Piper SandlerHold, reiterated$14−32.8%
+3.3%average 20-day move after past Neutral readings
+1.5%average move over the next 20 trading days in the last 5 years
±2.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Viatris seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Viatris averaged +1.5% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−7.8%2021−1.9%2022+9.9%2023+0.1%2024+8.8%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.9%2 of 5
Next 10 trading days−2.8%1 of 5
Next 15 trading days−1.7%2 of 5
Next 20 trading days+1.5%2 of 5
Next 30 trading days+4.5%2 of 5

For scale, VTRS’s typical 20-trading-day move in either direction is about 6.7%.

Viatris market cap and key statistics

Viatris’s market cap is $23.87B and revenue of $14.73B over the last twelve months.

Valuation

Market cap
$23.87B
Forward P/E
7.7
EPS, TTM
−$0.53
Gekko Fair Value
$19.31

Trading

Volume
6.51M
Avg volume, 20 days
9.55M
52-week high
$21.20
52-week low
$10.15
Shares outstanding
1.15B

Financials

Revenue, TTM
$14.73B
Profit margin
-4.1%
Return on equity
-4.2%
Quarterly earnings growth, YoY
−70.6%

Risk and income

Beta
0.87
Typical daily move
±2.9%
Typical 20-day move
±6.7%
Dividend yield
2.28%

Viatris peers

Viatris’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Viatris stock FAQ

What is Viatris’s market cap?

Viatris’s market cap is $23.87B at the Nov 13, 2026 close of $20.82, with 1.15B shares outstanding.

What is the Viatris stock forecast?

The consensus analyst 12-month price target for Viatris is $21.00, +0.9% from the last close. Of the 9 firms that rated the stock in the last 90 days, 5 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is Viatris stock overvalued or undervalued?

On Gekko’s estimate Viatris is overvalued: the Nov 13, 2026 close of $20.82 is 7.8% above Gekko Fair Value of $19.31. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Viatris report earnings next?

Viatris is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of $0.60 per share on revenue of $3.76B. Viatris beat the earnings estimate in 7 of its last 8 reports, moving 8.8% on average across the report.

What is Viatris’s 52-week high and low?

Viatris’s 52-week high is $21.20 and its 52-week low is $10.15; it closed at $20.82 on Nov 13, 2026, +89.1% over the past year.

Is Viatris stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Viatris the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.